Abstract 114P
Background
Therapeutic management of locally advanced gastric cancer (LAGC) combines surgery with neo-adjuvant (NACT) and adjuvant chemotherapy (ACT). miRNAs have emerged as promising candidates for treatment efficacy prediction, hence, the present study aims at defining therapy response-specific profiles of circulating miRNAin LAGC.
Methods
A prospective cohort of 26 LAGC patients scheduled for NACT, surgery and ACT treatment was considered. Peripheral blood samples were collected prior to (preNACT) and after NACT (postNACT) as well as after tumor surgical excision and by completion of ACT (postACT). Patients were grouped according to Becker’s tumor regression grade criteria into responders (R;TRG1-2) and non-responders (NR;TRG3). Serum RNA was isolated with magnetic bead technology and relative expression levels of miR21a, mir19a, mir20a, miR30a & miR15a were determined by qRT-PCR.
Results
PreNACT profiles revealed expression differences between R and NR patient groups, with Responders characterized by elevated miR21a and, particularly, miR30a and miR15a expression levels as compared to NR. In response to NACT, miR15a & miR30a downregulation was the most distinguished difference defining Responders. R profile also showed a distinct upregulation of mir21a and elevation of the initially low levels of mir20a & mir19a. In contrast, NR showed NACT-dependent upregulation of all targets except miR19a. Interestingly, it was surgical depletion of primary tumor that first led to a marked activation of studied miRNAs in both R and NR patients, an upregulation found further augmented after ACT treatment. Nevertheless, postACT miR15a and miR30a levels in R remained substantially lower than in NR, evidence adding to their potential as chemosensitivity indicators.
Conclusions
This study aimed at monitoring the consequential to oncological and surgical therapy response-dependent expression patterns of a panel of circulating miR and, despite the small case series, revealed the potential of, particularly, miR15a and miR30a as chemosensitivity predictors in LAGC. The evidence merits further investigation in larger patient cohorts to validate their clinical utility as biomarkes for stratifying GC patients for precision therapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National and Kapodistrian University of Athens, Greece.
Funding
ERAPerMed 2019-GRAMMY ERA Per Med - Joint Transnational Call for Proposals (2019) for “Personalised Medicine: Multidisciplinary Research Towards Implementation”.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract